| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medicare | 10 | 2020 | 625 | 2.030 |
Why?
|
| Population Health | 3 | 2024 | 17 | 1.780 |
Why?
|
| Preventive Health Services | 3 | 2016 | 75 | 1.370 |
Why?
|
| Medicaid | 4 | 2018 | 372 | 1.190 |
Why?
|
| Opiate Substitution Treatment | 2 | 2020 | 223 | 1.040 |
Why?
|
| Health Care Reform | 4 | 2015 | 86 | 1.020 |
Why?
|
| Reimbursement Mechanisms | 2 | 2015 | 41 | 0.900 |
Why?
|
| Opioid-Related Disorders | 3 | 2020 | 528 | 0.780 |
Why?
|
| Cardiovascular Diseases | 5 | 2018 | 863 | 0.760 |
Why?
|
| Quality of Health Care | 3 | 2016 | 528 | 0.750 |
Why?
|
| United States | 21 | 2024 | 8093 | 0.730 |
Why?
|
| Behavior Therapy | 2 | 2020 | 169 | 0.700 |
Why?
|
| Motivation | 1 | 2024 | 296 | 0.680 |
Why?
|
| Analgesics, Opioid | 3 | 2020 | 527 | 0.650 |
Why?
|
| Physician's Role | 3 | 2016 | 122 | 0.640 |
Why?
|
| Accountable Care Organizations | 3 | 2016 | 74 | 0.610 |
Why?
|
| Critical Pathways | 1 | 2020 | 31 | 0.610 |
Why?
|
| Delayed-Action Preparations | 1 | 2020 | 120 | 0.600 |
Why?
|
| Inappropriate Prescribing | 1 | 2020 | 68 | 0.590 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2020 | 104 | 0.590 |
Why?
|
| Health Promotion | 1 | 2024 | 516 | 0.590 |
Why?
|
| Drug Overdose | 1 | 2020 | 122 | 0.550 |
Why?
|
| Chronic Pain | 1 | 2020 | 156 | 0.530 |
Why?
|
| Machine Learning | 1 | 2019 | 195 | 0.510 |
Why?
|
| Fee-for-Service Plans | 2 | 2015 | 71 | 0.510 |
Why?
|
| Public Policy | 1 | 2016 | 38 | 0.480 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2020 | 706 | 0.460 |
Why?
|
| Dementia | 1 | 2019 | 280 | 0.460 |
Why?
|
| Career Choice | 1 | 2016 | 126 | 0.440 |
Why?
|
| Government Regulation | 1 | 2015 | 39 | 0.440 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 350 | 0.440 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2016 | 161 | 0.440 |
Why?
|
| Humans | 35 | 2024 | 65140 | 0.430 |
Why?
|
| Organizational Innovation | 1 | 2015 | 83 | 0.430 |
Why?
|
| Relative Value Scales | 1 | 2014 | 14 | 0.410 |
Why?
|
| Medical Oncology | 1 | 2014 | 69 | 0.410 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 347 | 0.390 |
Why?
|
| Social Determinants of Health | 1 | 2016 | 150 | 0.390 |
Why?
|
| Folate Receptors, GPI-Anchored | 1 | 2012 | 2 | 0.380 |
Why?
|
| Folic Acid | 1 | 2012 | 42 | 0.370 |
Why?
|
| Flecainide | 1 | 2012 | 3 | 0.370 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2012 | 32 | 0.360 |
Why?
|
| Health Services Accessibility | 2 | 2018 | 591 | 0.360 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2012 | 48 | 0.360 |
Why?
|
| Patient-Centered Care | 1 | 2014 | 256 | 0.350 |
Why?
|
| Autoantibodies | 1 | 2012 | 184 | 0.350 |
Why?
|
| Heart Defects, Congenital | 1 | 2012 | 101 | 0.340 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2012 | 162 | 0.330 |
Why?
|
| Blood Banks | 1 | 2010 | 9 | 0.320 |
Why?
|
| Anecdotes as Topic | 1 | 2010 | 11 | 0.320 |
Why?
|
| Pregnancy Outcome | 1 | 2012 | 197 | 0.320 |
Why?
|
| Chagas Disease | 1 | 2010 | 37 | 0.320 |
Why?
|
| Trypanosoma cruzi | 1 | 2010 | 53 | 0.320 |
Why?
|
| Adult | 11 | 2020 | 17358 | 0.300 |
Why?
|
| Heart | 1 | 2011 | 297 | 0.300 |
Why?
|
| Methadone | 2 | 2020 | 140 | 0.290 |
Why?
|
| Heart Diseases | 1 | 2011 | 223 | 0.290 |
Why?
|
| Adolescent | 6 | 2020 | 6297 | 0.280 |
Why?
|
| Physicians | 1 | 2014 | 474 | 0.280 |
Why?
|
| Female | 15 | 2020 | 34018 | 0.270 |
Why?
|
| Disorders of Sex Development | 1 | 2008 | 12 | 0.270 |
Why?
|
| Retrospective Studies | 6 | 2020 | 6872 | 0.270 |
Why?
|
| Health Care Costs | 3 | 2020 | 223 | 0.260 |
Why?
|
| Heart Ventricles | 2 | 2006 | 267 | 0.260 |
Why?
|
| Preimplantation Diagnosis | 1 | 2006 | 5 | 0.250 |
Why?
|
| Buprenorphine | 2 | 2020 | 198 | 0.250 |
Why?
|
| Young Adult | 6 | 2020 | 4809 | 0.250 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2006 | 37 | 0.250 |
Why?
|
| Pulmonary Atresia | 1 | 2006 | 2 | 0.240 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2006 | 7 | 0.240 |
Why?
|
| Reproduction | 1 | 2006 | 98 | 0.240 |
Why?
|
| Exercise Tolerance | 1 | 2006 | 85 | 0.230 |
Why?
|
| Male | 12 | 2020 | 31047 | 0.230 |
Why?
|
| Health Expenditures | 2 | 2018 | 121 | 0.230 |
Why?
|
| Empathy | 1 | 2006 | 69 | 0.230 |
Why?
|
| United States Indian Health Service | 1 | 2005 | 3 | 0.230 |
Why?
|
| Reimbursement, Incentive | 2 | 2016 | 29 | 0.230 |
Why?
|
| Computers | 1 | 2005 | 49 | 0.220 |
Why?
|
| Mass Screening | 1 | 2010 | 698 | 0.210 |
Why?
|
| Middle Aged | 7 | 2020 | 18273 | 0.210 |
Why?
|
| Cohort Studies | 2 | 2020 | 2620 | 0.200 |
Why?
|
| Community Health Services | 1 | 2005 | 127 | 0.200 |
Why?
|
| Health Education | 1 | 2005 | 189 | 0.200 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 5614 | 0.190 |
Why?
|
| Hospitalization | 2 | 2020 | 1392 | 0.180 |
Why?
|
| Physician-Patient Relations | 1 | 2006 | 425 | 0.180 |
Why?
|
| Fetal Diseases | 2 | 2012 | 22 | 0.180 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2006 | 268 | 0.180 |
Why?
|
| Incidence | 2 | 2019 | 1419 | 0.180 |
Why?
|
| Leadership | 2 | 2014 | 211 | 0.180 |
Why?
|
| Algorithms | 2 | 2019 | 1050 | 0.180 |
Why?
|
| Aged | 5 | 2020 | 14965 | 0.170 |
Why?
|
| Gestational Age | 2 | 2012 | 193 | 0.170 |
Why?
|
| Infant, Newborn | 3 | 2020 | 1422 | 0.170 |
Why?
|
| Parents | 1 | 2005 | 410 | 0.170 |
Why?
|
| New Mexico | 2 | 2014 | 9 | 0.160 |
Why?
|
| Drug Tolerance | 1 | 2020 | 33 | 0.160 |
Why?
|
| Comparative Effectiveness Research | 1 | 2020 | 46 | 0.150 |
Why?
|
| Naltrexone | 1 | 2020 | 91 | 0.150 |
Why?
|
| Child | 3 | 2020 | 4607 | 0.150 |
Why?
|
| Datasets as Topic | 1 | 2019 | 29 | 0.150 |
Why?
|
| Physical Therapy Modalities | 1 | 2019 | 46 | 0.150 |
Why?
|
| Infant | 2 | 2020 | 1693 | 0.150 |
Why?
|
| Treatment Outcome | 4 | 2020 | 5792 | 0.150 |
Why?
|
| Pyridones | 1 | 2019 | 42 | 0.150 |
Why?
|
| Narcotic Antagonists | 1 | 2020 | 133 | 0.150 |
Why?
|
| Indoles | 1 | 2019 | 112 | 0.140 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 1282 | 0.140 |
Why?
|
| Low Back Pain | 1 | 2019 | 112 | 0.140 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2018 | 22 | 0.140 |
Why?
|
| Mortality | 1 | 2019 | 161 | 0.140 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 164 | 0.140 |
Why?
|
| Long-Acting Reversible Contraception | 1 | 2018 | 3 | 0.140 |
Why?
|
| Ambulatory Care | 1 | 2020 | 317 | 0.140 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 740 | 0.130 |
Why?
|
| Family Planning Services | 1 | 2018 | 20 | 0.130 |
Why?
|
| Pregnancy, Unplanned | 1 | 2018 | 22 | 0.130 |
Why?
|
| Pregnancy | 3 | 2018 | 2372 | 0.130 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2019 | 161 | 0.130 |
Why?
|
| Longevity | 1 | 2018 | 117 | 0.130 |
Why?
|
| Patient Care | 1 | 2017 | 79 | 0.130 |
Why?
|
| Curriculum | 2 | 2016 | 608 | 0.130 |
Why?
|
| Weight Reduction Programs | 1 | 2017 | 63 | 0.120 |
Why?
|
| Organizational Objectives | 1 | 2016 | 59 | 0.120 |
Why?
|
| Policy Making | 1 | 2016 | 48 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2012 | 1141 | 0.120 |
Why?
|
| Health Policy | 1 | 2018 | 191 | 0.120 |
Why?
|
| Age Factors | 1 | 2020 | 1586 | 0.120 |
Why?
|
| Prevalence | 1 | 2020 | 1445 | 0.120 |
Why?
|
| Schools, Medical | 1 | 2016 | 150 | 0.110 |
Why?
|
| Value-Based Purchasing | 1 | 2015 | 8 | 0.110 |
Why?
|
| Primary Prevention | 1 | 2016 | 136 | 0.110 |
Why?
|
| Cost Savings | 1 | 2016 | 58 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2018 | 262 | 0.110 |
Why?
|
| Surveys and Questionnaires | 3 | 2010 | 2757 | 0.110 |
Why?
|
| Prognosis | 2 | 2012 | 1784 | 0.110 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 121 | 0.110 |
Why?
|
| Child, Preschool | 1 | 2020 | 2061 | 0.110 |
Why?
|
| Legislation as Topic | 1 | 2014 | 12 | 0.100 |
Why?
|
| Health Services Needs and Demand | 1 | 2016 | 219 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 2483 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 734 | 0.100 |
Why?
|
| Neural Tube Defects | 1 | 2012 | 28 | 0.090 |
Why?
|
| Immunoglobulin M | 1 | 2012 | 116 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2015 | 742 | 0.090 |
Why?
|
| Digoxin | 1 | 2012 | 23 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 1 | 2014 | 252 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 213 | 0.090 |
Why?
|
| Reference Values | 1 | 2012 | 327 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 296 | 0.090 |
Why?
|
| Echocardiography, Doppler | 1 | 2012 | 133 | 0.090 |
Why?
|
| Electric Countershock | 1 | 2012 | 105 | 0.080 |
Why?
|
| Administration, Oral | 1 | 2012 | 371 | 0.080 |
Why?
|
| Blood Donors | 1 | 2010 | 22 | 0.080 |
Why?
|
| Mexico | 1 | 2010 | 39 | 0.080 |
Why?
|
| Exercise | 1 | 2017 | 964 | 0.080 |
Why?
|
| Immunoglobulin G | 1 | 2012 | 465 | 0.080 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 431 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 856 | 0.080 |
Why?
|
| Incidental Findings | 1 | 2010 | 51 | 0.080 |
Why?
|
| Professional Competence | 1 | 2010 | 91 | 0.080 |
Why?
|
| Myocardial Infarction | 1 | 2016 | 919 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2016 | 2102 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 1163 | 0.070 |
Why?
|
| Obesity | 1 | 2017 | 1274 | 0.070 |
Why?
|
| Blood Transfusion | 1 | 2010 | 165 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 317 | 0.070 |
Why?
|
| Nurses | 1 | 2010 | 110 | 0.070 |
Why?
|
| Genitalia | 1 | 2008 | 9 | 0.070 |
Why?
|
| Adrenal Hyperplasia, Congenital | 1 | 2008 | 5 | 0.070 |
Why?
|
| Circumcision, Male | 1 | 2008 | 8 | 0.070 |
Why?
|
| Stroke | 1 | 2016 | 1211 | 0.060 |
Why?
|
| Gender Identity | 1 | 2008 | 68 | 0.060 |
Why?
|
| Neoplasms | 1 | 2017 | 1368 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 1559 | 0.060 |
Why?
|
| Dwarfism | 1 | 2006 | 15 | 0.060 |
Why?
|
| Donor Selection | 1 | 2006 | 15 | 0.060 |
Why?
|
| Embryo Transfer | 1 | 2006 | 24 | 0.060 |
Why?
|
| Homosexuality, Female | 1 | 2006 | 22 | 0.060 |
Why?
|
| Hydrocortisone | 1 | 2008 | 192 | 0.060 |
Why?
|
| Choice Behavior | 1 | 2006 | 85 | 0.060 |
Why?
|
| Deafness | 1 | 2006 | 36 | 0.060 |
Why?
|
| Sex Characteristics | 1 | 2008 | 213 | 0.060 |
Why?
|
| American Heart Association | 2 | 2016 | 128 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 767 | 0.060 |
Why?
|
| Hypoplastic Left Heart Syndrome | 1 | 2004 | 3 | 0.050 |
Why?
|
| Risk Factors | 2 | 2016 | 5429 | 0.050 |
Why?
|
| Exercise Test | 1 | 2006 | 257 | 0.050 |
Why?
|
| Aneurysm, False | 1 | 2004 | 47 | 0.050 |
Why?
|
| Pulmonary Artery | 1 | 2004 | 96 | 0.050 |
Why?
|
| Electrocardiography | 1 | 2006 | 554 | 0.050 |
Why?
|
| Plants, Medicinal | 1 | 2002 | 19 | 0.050 |
Why?
|
| Education, Distance | 1 | 2002 | 35 | 0.050 |
Why?
|
| Education, Medical, Continuing | 1 | 2002 | 92 | 0.040 |
Why?
|
| Communication | 1 | 2006 | 596 | 0.040 |
Why?
|
| Embolization, Therapeutic | 1 | 2004 | 333 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2002 | 236 | 0.040 |
Why?
|
| Internet | 1 | 2002 | 467 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2006 | 3308 | 0.040 |
Why?
|
| Propensity Score | 1 | 2019 | 190 | 0.030 |
Why?
|
| Cause of Death | 1 | 2019 | 221 | 0.030 |
Why?
|
| Health Personnel | 1 | 2002 | 384 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 197 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2018 | 76 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 202 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2004 | 1326 | 0.030 |
Why?
|
| Tobacco Use Cessation | 1 | 2016 | 32 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 2017 | 174 | 0.030 |
Why?
|
| Body Weight | 1 | 2017 | 376 | 0.030 |
Why?
|
| Logistic Models | 1 | 2019 | 1269 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2019 | 443 | 0.030 |
Why?
|
| Cancer Survivors | 1 | 2017 | 129 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2015 | 106 | 0.030 |
Why?
|
| Aspirin | 1 | 2016 | 172 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 496 | 0.030 |
Why?
|
| Cardiology | 1 | 2016 | 170 | 0.030 |
Why?
|
| Cost Control | 1 | 2014 | 24 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 214 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 805 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2016 | 526 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2019 | 721 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 324 | 0.020 |
Why?
|
| Quality of Life | 1 | 2017 | 1260 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 2701 | 0.020 |
Why?
|
| Prosthesis-Related Infections | 1 | 2004 | 34 | 0.010 |
Why?
|
| Abscess | 1 | 2004 | 78 | 0.010 |
Why?
|
| Staphylococcal Infections | 1 | 2004 | 130 | 0.010 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2004 | 214 | 0.010 |
Why?
|
| Radiography | 1 | 2004 | 555 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2002 | 164 | 0.010 |
Why?
|
| Palliative Care | 1 | 2004 | 249 | 0.010 |
Why?
|
| Educational Measurement | 1 | 2002 | 213 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2002 | 587 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2002 | 493 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2002 | 726 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2002 | 624 | 0.010 |
Why?
|